| Identification | Back Directory | [Name]
Baloxavir | [CAS]
1985605-59-1 | [Synonyms]
CPD2051
S-033447
Baloxavir
New Baloxavir
Baloxavir (Xofluza
Baloxavir USP/EP/BP
Baloxavir Impurity 10
BXA,endonuclease,S033447,Influenza Virus
influenza,RNA,inhibit,dolutegravir,Baloxavir,Inhibitor,cap-dependent,S 033447,CEN,transcription,replication
(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2’4]triazine-6,8- dione
(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03?]tetradeca-10,13-diene-9,12-dione
(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione
(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione
1H-[1,4]Oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, 12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,12,12a-tetrahydro-7-hydroxy-, (12aR)-
1H-[1,4]Oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione,12-[(11S)-7Chemicalbook,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,12,12a-tetrahydro-7-hydroxy-,(12aR)- | [EINECS(EC#)]
200-001-8 | [Molecular Formula]
C24H19F2N3O4S | [MDL Number]
MFCD31619273 | [MOL File]
1985605-59-1.mol | [Molecular Weight]
483.49 |
| Questions And Answer | Back Directory | [Uses]
Baloxavir is a drug employed in the treatment of influenza virus infection.
Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. |
| Chemical Properties | Back Directory | [Boiling point ]
644.7±65.0 °C(Predicted) | [density ]
1.63±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:41.67(Max Conc. mg/mL);86.19(Max Conc. mM) | [form ]
A solid | [pka]
4.50±1.00(Predicted) | [CAS DataBase Reference]
1985605-59-1 |
| Hazard Information | Back Directory | [Mechanism of action]
Baloxavir marboxil is an influenza therapeutic agent, specifically, an enzyme inhibitor targeting the influenza virus' cap-dependent endonuclease activity, one of the activities of the virus polymerase complex. In particular, it inhibits a process known as cap snatching, by which the virus derives short, capped primers from host cell RNA transcripts, which it then uses for polymerase-catalyzed synthesis of its needed viral mRNAs. A polymerase subunit binds to the host pre-mRNAs at their 5' caps, then the polymerase's endonuclease activity catalyzes its cleavage "after 10–13 nucleotides". As such, its mechanism is distinct from neuraminidase inhibitors such as oseltamivir and zanamivir. | [Side effects]
Common side effects following the single dose administration of baloxavir marboxil include diarrhea, bronchitis, common cold, headache, and nausea. Adverse events were reported in 21% of people who received baloxavir, 25% of those receiving placebo, and 25% of oseltamivir. | [storage]
Store at -20°C |
|
|